Literature DB >> 16330984

The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty.

Vincent D Pellegrini1, Christopher T Donaldson, Daniel C Farber, Erik B Lehman, C McCollister Evarts.   

Abstract

UNLABELLED: Venous thromboembolic disease remains the most common reason for readmission after total hip arthroplasty. Prospective analysis of screening contrast venography was done from 1984 to 2003 in 1972 patients having elective total hip arthroplasty. Patients with deep venous thrombosis or pulmonary embolism received warfarin therapy; those with negative venograms received no further anticoagulation. From 1984 to 1992, patients not completing venography were discharged without warfarin; since 1993, patients without venography received warfarin for 6 weeks. Readmission for deep venous thrombosis, pulmonary embolism, or bleeding was tracked for 6 months. Venograms were completed in 1032 patients; 175 (16.9%) had deep venous thrombosis. Deep venous thrombosis was reduced by a clinical pathway that included continuous epidural anesthesia (14.2% versus 22.5%). The overall readmission rate for venous thromboembolic disease was 1.62%, including 14 pulmonary emboli (three fatal) and 18 femoral deep venous thrombosis. Readmission occurred in 0.27% (1 of 360) patients on continued warfarin, compared with 2.2% (19 of 880) with negative venograms discharged without further anticoagulation. Three patients (0.15%) suffered fatal pulmonary emboli; all had negative venograms and received no outpatient prophylaxis. Extended outpatient warfarin therapy provided effective protection against venous thromboembolic disease readmission. Surveillance venography was a poor predictor of need for continued prophylaxis; all patients should have extended anticoagulation after total hip arthroplasty. LEVEL OF EVIDENCE: Therapeutic study, Level I-1 (high-quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals). See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330984     DOI: 10.1097/01.blo.0000194726.55372.4d

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  10 in total

Review 1.  A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

Authors:  Sam Schulman; Ammar Majeed
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

Review 2.  New anticoagulants for the prevention of venous thromboembolism.

Authors:  Cecilia Becattini; Alessandra Lignani; Giancarlo Agnelli
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

Review 3.  Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review.

Authors:  Davide Imberti; Chiara Dall'Asta; Matteo Giorgi Pierfranceschi
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

4.  Discontinuation of warfarin is unnecessary in total knee arthroplasty.

Authors:  David A Rhodes; Erik P Severson; Jeffrey T Hodrick; Harold K Dunn; Aaron A Hofmann
Journal:  Clin Orthop Relat Res       Date:  2010-01       Impact factor: 4.176

5.  Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary?

Authors:  Gregory G Polkowski; Stephen T Duncan; Adam D Bloemke; Perry L Schoenecker; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2014-04-15       Impact factor: 4.176

Review 6.  New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

Authors:  Ola E Dahl
Journal:  Vasc Health Risk Manag       Date:  2012-01-25

7.  Oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate.

Authors:  D Kendoff; C Perka; H M Fritsche; T Gehrke; R Hube
Journal:  Open Orthop J       Date:  2011-12-30

Review 8.  Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years.

Authors:  Zi-hao Zhang; Bin Shen; Jing Yang; Zong-ke Zhou; Peng-de Kang; Fu-xing Pei
Journal:  BMC Musculoskelet Disord       Date:  2015-02-10       Impact factor: 2.362

9.  Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol.

Authors:  Vincent D Pellegrini; John William Eikelboom; C McCollister Evarts; Patricia D Franklin; Kevin L Garvin; Samuel Z Goldhaber; Richard Iorio; Carol Ann Lambourne; Jay Magaziner; Laurence Magder
Journal:  BMJ Open       Date:  2022-03-08       Impact factor: 2.692

10.  What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients?

Authors:  Alisina Shahi; Thomas L Bradbury; George N Guild; Usama Hassan Saleh; Elie Ghanem; Ali Oliashirazi
Journal:  Arthroplast Today       Date:  2018-05-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.